Sonic Healthcare (ASX:SHL) Full Year 2025 Results

Key Financial Results

Revenue: AU$9.65b (up 7.6% from FY 2024). Net income: AU$513.6m (flat on FY 2024). Profit margin: 5.3% (down from 5.7% in FY 2024). The decrease in margin was driven by higher expenses. EPS: AU$1.07.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.ASX:SHL Revenue and Expenses Breakdown August 26th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sonic Healthcare EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.2%.

The primary driver behind last 12 months revenue was the Laboratory segment contributing a total revenue of AU$8.19b (85% of total revenue). Notably, cost of sales worth AU$6.46b amounted to 67% of total revenue thereby underscoring the impact on earnings.Explore how SHL's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare industry in Australia.

Performance of the Australian Healthcare industry.

The company's shares are down 18% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Sonic Healthcare that you need to take into consideration.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments